Growth momentum Revvity and OMNI International show strong revenue growth signals with quarterly earnings beats and ongoing expansion into large-scale screening and automated TB testing platforms, presenting opportunities to cross-sell advanced lab automation, data integration, and diagnostic workflows.

Automation push Revvity's development of automated TB platforms and high-throughput testing systems indicates a strategic emphasis on scalable laboratory automation, creating sales angles for ELK data analytics, workflow orchestration, and software-enabled instrumentation.

Strategic partnerships Recent partnerships, including Rompa Group for ISO cleanroom production and ongoing collaborations, suggest a favorable channel for expanding distribution, integration services, and co-development opportunities in new geographies and regulated environments.

Integrated tech OMNI operates within a Revvity ecosystem leveraging diverse tech like Power Apps, SharePoint, and elastic data stacks, signaling opportunities to propose enterprise data management, custom apps, and CRM/marketing automation enhancements for life sciences customers.

Market expansion Launch of advanced prenatal and TB screening platforms points to growing demand in diagnostic testing and high-throughput laboratories, indicating upsell potential for supply chain optimization, QA systems, and cloud-based analytics to support scale.